Meropenem-clavulanic acid has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis.
Lina Davies ForsmanC G GiskeJ BruchfeldT SchönP JuréenK ÄngebyPublished in: Antimicrobial agents and chemotherapy (2015)
We investigated the activity of meropenem-clavulanic acid (MEM-CLA) against 68 Mycobacterium tuberculosis isolates. We included predominantly multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) isolates, since the activity of MEM-CLA for resistant isolates has previously not been studied extensively. Using Middlebrook 7H10 medium, all but four isolates showed an MIC distribution of 0.125 to 2 mg/liter for MEM-CLA, below the non-species-related breakpoint for MEM of 2 mg/liter defined by EUCAST. MEM-CLA is a potential treatment option for MDR/XDR-TB.
Keyphrases
- multidrug resistant
- drug resistant
- mycobacterium tuberculosis
- gram negative
- acinetobacter baumannii
- genetic diversity
- klebsiella pneumoniae
- pulmonary tuberculosis
- mass spectrometry
- high resolution
- pseudomonas aeruginosa
- climate change
- emergency department
- drug induced
- risk assessment
- human health
- african american
- high speed
- adverse drug